Evidence map›Paper›PMID 36275650›Full record

ArticleFrontiers in immunology2022

Bet v 1-displaying elastin-like polypeptide nanoparticles induce a strong humoral and weak CD4+ T-cell response against Bet v 1 in a murine immunogenicity model.

Jolinde van Strien, Hans Warmenhoven, Adrian Logiantara, Max Makurat, Lorenz Aglas, Athanasios Bethanis, Romain Leboux, Leonie van Rijt, J Andrew MacKay, Johannes W van Schijndel and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 6 institutions in 3 countries.

Jolinde van StrienDepartment of Supramolecular and Biomaterials Chemistry, Leiden Institute of Chemistry, Leiden University, Leiden, Netherlands.
Hans WarmenhovenDepartment of Experimental Immunology, Amsterdam University Medical Centers, Amsterdam, Netherlands.
Adrian LogiantaraDepartment of Experimental Immunology, Amsterdam University Medical Centers, Amsterdam, Netherlands.
Max MakuratDepartment of Supramolecular and Biomaterials Chemistry, Leiden Institute of Chemistry, Leiden University, Leiden, Netherlands.
Lorenz AglasDivision of Allergy and Immunology, Department of Biosciences, Paris Lodron University of Salzburg, Salzburg, Austria.
Athanasios BethanisDivision of Allergy and Immunology, Department of Biosciences, Paris Lodron University of Salzburg, Salzburg, Austria.
Romain LebouxDepartment of BioTherapeutics, Leiden Academic Centre for Drug Research (LACDR), Leiden University, Leiden, Netherlands.
Leonie van RijtDepartment of Experimental Immunology, Amsterdam University Medical Centers, Amsterdam, Netherlands.
J Andrew MacKayDepartment of Pharmacology and Pharmaceutical Sciences, School of Pharmacy, University of Southern California, Los Angeles, CA, United States.
Johannes W van SchijndelR&D Department, Haarlems Allergenen Laboratorium (HAL) Allergy B.V., Leiden, Netherlands.
Gregory SchneiderDepartment of Supramolecular and Biomaterials Chemistry, Leiden Institute of Chemistry, Leiden University, Leiden, Netherlands.
René OlsthoornDepartment of Supramolecular and Biomaterials Chemistry, Leiden Institute of Chemistry, Leiden University, Leiden, Netherlands.
Wim JiskootDepartment of BioTherapeutics, Leiden Academic Centre for Drug Research (LACDR), Leiden University, Leiden, Netherlands.
Ronald van ReeDepartment of Experimental Immunology, Amsterdam University Medical Centers, Amsterdam, Netherlands.
Alexander KrosDepartment of Supramolecular and Biomaterials Chemistry, Leiden Institute of Chemistry, Leiden University, Leiden, Netherlands.
Leiden University · NLAmsterdam University Medical Centers · NLCentre for Human Drug Research · NLUniversity of Salzburg · ATHAL Allergy (Netherlands) · NLUniversity of Southern California · US

Funding

Intracellular switching using genetically engineered protein microdomainsR01GM114839 · NIGMS · UNIVERSITY OF SOUTHERN CALIFORNIA · PI MACKAY, JOHN ANDREW · 2015 to 2019
$1.9M
Austrian Science Fund FWF P 32189NIGMS NIH HHS R01 GM114839
6 · The paper itself

Abstract

There is growing concern about the toxicity of colloidal aluminum salts used as adjuvants in subcutaneous allergen immunotherapy (SCIT). Therefore, alternative adjuvants and delivery systems are being explored to replace alum in SCIT. We applied micellar elastin-like polypeptides (ELPs), a type of self-assembling protein, to replace alum as vaccine adjuvant in birch pollen SCIT. ELP and an ELP-Bet v 1 fusion protein were expressed in

Indexed as

Antigens, PlantNanoparticlesAllergensAlum CompoundsAluminumAnimalsCD4-Positive T-LymphocytesCytokinesElastinEscherichia coliHumansImmunoglobulin EImmunoglobulin GMiceMicellesPeptidesAllergensAlum CompoundsAluminumaluminum sulfateAntigens, PlantCytokinesElastinImmunoglobulin EImmunoglobulin GMicellesPeptidesSaltsaluminumBet v 1elastin-like polypeptidehypo-allergenicmouse modelnanoparticles

Identifiers

PMID36275650
PMCPMC9583423
OpenAlexW4302304792

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.